Solid biosciences to present at the 2025 muscular dystrophy association (mda) clinical & scientific conference

Charlestown, mass., march 12, 2025 (globe newswire) -- solid biosciences inc. (nasdaq: sldb), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, will present data from the phase 1/2 inspire duchenne trial evaluating sgt-003, a next-generation gene therapy product candidate intended for the treatment of duchenne muscular dystrophy (duchenne), at the 2025 muscular dystrophy association (mda) clinical & scientific conference, taking place in dallas, tx, march 16-19, 2025.
SLDB Ratings Summary
SLDB Quant Ranking